Overview
McDermott Will & Emery advised One Biosciences, a precision oncology techbio company pioneering clinical single-cell tumor transcriptomic profiling, on its Series A financing.
The funding will be used to establish the clinical utility of OneMap, a proprietary AI-driven-single-cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trials.
Proceeds will also help scale strategic partnerships with pharmaceutical and biotechnology companies.
The financing round was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures.
The McDermott team comprised:
● Emmanuelle Trombe, partner, Ludivine Rabreau and Oriana Castelli, associates
